4.20Open4.20Pre Close0 Volume5 Open Interest12.50Strike Price0.00Turnover0.00%IV10.46%PremiumJul 19, 2024Expiry Date3.23Intrinsic Value100Multiplier6DDays to Expiry0.97Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma3.01Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Profound Medical Stock Discussion
Profound Medical Announces Category 1 CPT Codes Proposed CY2025 Rule for TULSA to Treat Prostate Diseases
Profound Medical announced the U.S. Centers for Medicare and Medicaid Services (CMS) proposed a Category 1 CPT code for Transurethral Ultrasound Ablation (TULSA), effective January 1, 2025. This includes three physician codes for different procedural scenarios, introducing greater billing flexibility for pre and post-procedure visits.
TULSA will be recognize...
NEWS
Growing Body of Clinical Evidence Points to the Potential of Profound Medical’s TULSA Procedure Becoming a Mainstream Treatment Modality Across the Entire Prostate Disease Spectrum
Profound Medical Corp.'s TULSA procedure is gaining recognition as a mainstream treatment for prostate diseases, with 25 scientific research presentations this year alone. The clinical evidence showcases TULSA's efficacy in treating a diverse range of patients with localized prostate c...
No comment yet